HUMAN ANTIBODIES & HYBRIDOMAS 2020
Nascent Biotech founder Dr. Mark C. Glassy will once again be organizing and speaking at the Human Antibodies & Hybridomas conference, held 11-13 November 2020, The Richard Doll Building, [...]
Recent Publications from Nascent Biotech Founder Dr. Mark C. Glassy
Click each link to download individual publications in PDF format. Brain‐derived neurotrophic factor downregulation in gastric cancer Antibody drug conjugates: Progress, pitfalls, and promises [...]
Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises
Nascent Biotech founder Dr. Mark C. Glassy has co-authored a new paper appearing in Human Antibodies entitled, “Antibody drug conjugates: Progress, pitfalls, and promises.” Please [...]
Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer
Vero Beach, FL December 10, 2018 – Nascent Biotech, Inc. (OTC: NBIO) Received US Food and Drug Administration (FDA) Clearance to begin Phase 1 Clinical Trials effective December 7th, 2018. [...]
Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associated autologous anti-vimentin antibody, CLN-IgG (Pritumumab)
The British Journal of Cancer Research has just released a new paper co-authored by Nascent Biotech founder Dr. Mark C. Glassy entitled, “Prionogenicity of vimentin surmised from the [...]
Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with [...]
The Economist: Closing In On Cancer
The Economist has published a fascinating overview of cancer research’s progress, including immunotherapy: The greatest excitement is reserved for immunotherapy, a new approach that has [...]
Nascent Biotech Retires Liabilities with Non-Dilutive Funding
Vero Beach FL, August 10, 2016 – Nascent Biotech, Inc., (“Nascent” or “the Company”) (BB: NBIO) is pleased to announce that through the non-dilutive funding recently received, it has paid nearly [...]
Nascent Biotech and Hisun Announce an Exclusive License Agreement for the Development and Commercialization of Nascent’s Primary Asset, Pritumumab, in Mainland China
Development planned for multiple Epithelial Cancer Types, starting with brain cancer, in Mainland China. July 18, 2016 10:00 am EDT Dateline: TAIZHOU, Zhejiang Province, China & Vero Beach, [...]
Nascent Biotech Announces Orphan Drug Designation for Pancreatic Cancer
Vero Beach, April 25th, 2016 – Nascent Biotech, Inc., (OTC.NBIO) is pleased to announce that it has been granted Orphan Drug Designation from the Office of Orphan Products Development of the FDA [...]